• Chapter 28: Which Makes More Sense?
• Chapter 29: Adding Vitamins to Statin Drugs

Chapter Excerpts by Ladd McNamara, M.D.

Medications, even taken the way they’re prescribed, are the third leading cause of death in the United States after cardiovascular disease and cancer. Over 100,000 people die every year in the United States from taking prescription medications.

According to Dr. Ladd McNamara, the drug manufacturers will never admit that it is the antioxidants that reduce disease and death. In order to make money, the industry needs to sell you patented drugs, …not convince you that you should be taking vitamins and minerals.

Chapter References

• 56: Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004. Mar;173(1):1-12.
• 57: Tsimikas S, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14;110(11):1406-12.
• 58: Sparks DL., et al. Statin therapy in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:78-86.
• 59: Wolozin B., et al. Re-assessing the relationship between cholesterol, statins and Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:63-70.
• 60: Nunomura A, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006. Jul;65(7):631-41.
• 61: Harman D. Alzheimer’s disease pathogenesis: role of aging. Ann NY Acad Sci. 2006 May;1067:454-60.
• 62: Moreira PI, et al. Therapeutic options in Alzheimer’s disease. Expert Rev Neurother. 2006 Jun;6(6):897-910.
• 63: Ono K., et al. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer’s disease. Biochim Biophys Acta. 2006 Jun;1762(6):575-86.
• 64: Montiel T, et al. Role of oxidative stress on beta-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: Protection by antioxidants. Exp Neurol. 2006 Apr 18; [Epub ahead of print].
• 65: Ono K, Yamada M. Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. 2006 Apr;97(1):105-15. Epub 2006 Mar 8.
• 66: Hajieva P, Behl C. Antioxidants as a potential therapy against age-related neurodegenerative diseases: amyloid Beta toxicity and Alzheimer’s disease. Curr Pharm Des. 2006;12(6):699-704.
• 38: Langsjoen P, Langsjoen A. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003 18(1-4):101-111.
• 67: Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ugiquinol/ubiqinone without affecting other antioxidants and PUFA. Biofactors 2003 18(1-4):113-124.
• 68: Mortensen S, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997 18(suppl):S137-S144.
• 69: Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q10 levels in humans. Proc Natl Acad Sci USA. 1990 Nov; 87(22):8931-8934.
• 70: Quiles J, Farquharson A, Ramirez-Tortosa M, et al. Coenzyme Q10 differentially moderates phospholipid hydroperoxide glutathionate peroxidase gene expression and free radicals production in malignant and non-malignant prostate cancer. Biofactors 2003 18(1-4):265-270.

• Chapter 25: Statin Drugs May Cause Depression and Possibly Suicide
• Chapter 26: Statin Drugs Impair Memory and the Ability to Think
• Chapter 27: Statin Drugs may Cause Cancer

Chapter Excerpts by Ladd McNamara, M.D.

Fifteen percent of those taking statin drugs develop some cognitive side effects.

Dr. Ladd McNamara is concerned that the pharmaceutical industry denies that statin drugs can cause amnesia; yet in many of their own studies, memory loss was reported.

Over 5 years, of the approximately 250 women taking Lipitor®, there were 12 new cases of breast cancers, compared to one new case among the placebo group. Certainly not proof that statin drugs cause breast cancer, but a 1500% increase risk of breast cancer is enough"smoke" to be worried about a fire.

Because Co-Q10 levels are decreased by statin drugs, it is easy for Dr. Ladd McNamara to predict that we will see an increased risk of prostate and breast cancer as a result.

Chapter References by Ladd McNamara, M.D.

• 43: King D, Wilburn A, Wofford M, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003 Dec; 23(12):1663-1667.
• 44: Muldoon M, Barger S, Ryan C, Flory J, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000 May; 108(7):538-546.
• 45: Eleanor Laise. The Lipitor Dilemma, Smart Money: The Wall Street Journal Magazine of Personal Business, November 2003.
• 46: Duane Graveline, MD., Lipitor: Thief of Memory, 2004, www.buybooksontheweb.com.
• 47: Lopena O, Pharm D, Pfizer, Inc., written communication, 2002. Quoted in an email communication from Duane Graveline, spacedoc@webtv.net.
• 48: Leung, B, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003 170:1524-1530.
• 49: Palinski, W, et al. Immunomodulation: a new role for statins? Nature Medicine, 2000 Dec 6(12):1311-1312.
• 50: Newman T, Hulley S. Carcinogenicity of lipid-lowering drugs. JAMA 1996 Jan 3; 275(1):55-60.
• 51: Folkers K, et al. Activities of Vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997 234(2):296-299.
• 52: Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun, 1995 Jul 6; 212(1):172-7.
• 53: Sacks F, Pfeffer M, Moye L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3; 335(14):1001-1009.
• 54: Boudreau D, Gardner J, Malone K, et al. The association between 3-hydroxy-3-methylglutaryl co-enzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004 Jun 1; 100(11):2308-2316.
• 55: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002 Jul 6; 360(9326):7-22.

• Chapter 16: Conspiracy to Have Everyone Taking Cholesterol-Lowering Drugs
• Chapter 17: The Cholesterol-Lowering Statin Drugs and the New Recommendations

Chapter Excerpts

Only 30-40% of people with blocked arteries and heart disease have elevated blood cholesterol levels, and posed the logical question: "How do you explain the other 60 to 70 %?"

The level at which LDL cholesterol is considered normal has continually been influenced by pharmaceutical companies, who pull the financial strings of research grants that keep medical schools and medical organizations running. The lower they can establish the level at which LDL cholesterol is considered normal, the more people automatically become victims of the dreaded disease of "high cholesterol."

The fact is eight of the nine panel members making the new LDL cholesterol recommendations were being paid by the statin-producing pharmaceutical companies. The panelists did not disclose their financial conflict of interest.

Chapter References

• 17: Rafai N, Ridker P. Inflammatory markers and coronary heart disease. Curr Opin Lipidol 2002 Aug; 13(4):383-389.
• 18: Albert C, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 Jun 4; 105 (22):2595-2599.
• 19: Bermudez E, Ridker P. C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 2002 Winter; 5(1):42-46.
• 20: Blake C, Ridker P. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2001 Nov; 2(11):796-800.
• 21: Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ; for the Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 110:227-239.

• Chapter 14: "Doctors Would Not Recommend Cholesterol-lowering Drugs if they Were Not Good for Us, Right?"
• Chapter 15: Medical Ethics and Conflict of Interest in Scientific Medicine

Chapter Excerpts

Most doctors are not "in" on the cholesterol conspiracy. They are just as much victims to it as is the public. Doctors are only doing what they learn both directly and indirectly from the pharmaceutical companies.

What the American public did not know, however, was that the tobacco industry funded and supported most of the latest and "up-to-date" research about the "safety" of cigarette smoking. This is not unlike today’s pharmaceutical companies funding the latest and most "upto-date" research regarding the "safety" of their drugs.

According to the medical experts, the medical research, with the American Cancer Society and the "all-powerful, all-knowing" American Medical Association concurring, the world now knew without any doubt that not only was cigarette smoking unharmful, but that it actually helped reduce lung cancer.

An ABC report noted that a survey of clinical trials revealed that when drug companies did not fund a study, favorable results regarding a drug were found only 50 percent of the time. In studies funded by drug companies, favorable results about the drugs were reported an amazing 90% of the time.

The amount of money the pharmaceutical companies give to colleges and universities to obtain the results they want is staggering, and it is getting worse.

Chapter References

• 12: Tobacco Timeline. http://www.tobacco.org.
• 13: Weiner J. Smoking and Cancer: The Cigarette Papers: How the Industry is Trying to Smoke Us All. The Nation, January 1, 1996 11-18.
• 14: World Health Organization, Press Release Bulletin #9, Dec. 17, 2001.
• 15: Angell M. Is academic medicine for sale? N Engl J Med. 2000 May 18; 342(20):1516-1518.
• 16: Crossen C. Tainted Truth: The Manipulation of Fact in America. 1996. Touchstone Books.

• Chapter 12: Conflicting Studies?
• Chapter 13: The Pharmaceutical Industry’s Money Influences the Treatment of Disease

Chapter Excerpts by Ladd McNamara, M.D.

In this study they never lowered homocysteine to what research has shown to be a safe and effective level, which is 6.5 or less. In fact, for every 3 points above 6.5 there is a 35% increase risk of heart disease.

Ladd McNamara, M.D.

Chapter References by Ladd McNamara, M.D.

• 11: Bonaa KH, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006. Apr 13;354(15):1578-88.

Ladd McNamara, M.D.

• Chapter 5: How the Pharmaceutical Industry Influences Medical Education
• Chapter 6: The Myth that High Cholesterol Causes Heart Disease
• Chapter 7: The Number One Cause of Death in the United States

Chapter Excerpts by Ladd McNamara, M.D.

It was only about ten years ago that the Surgeon General declared that 68% of all disease is caused by diet.
That would make a poor diet the number one cause of ill health in the United States, not the omission of prescription drugs.
Dr. Ladd McNamara defines a poor diet as a lack of vitamins, minerals, antioxidants, essential fatty acids.

As there was more money to be made from pharmaceutical development, the campaign to produce cholesterol-lowering drugs kicked into high gear, despite the lack of evidence showing that lowering cholesterol reduced the risk of death from heart disease.